摘要:
A method for producing a drug substance of crystalline pitavastatin calcium excellent in stability, is presented. In the production of a compound (pitavastatin calcium) represented by the formula (1): The water content is adjusted to a level of from 5 to 15%, and the crystal form is controlled to be crystal form A, thereby to obtain a drug substance excellent in stability.
摘要:
A method for producing a drug substance of crystalline pitavastatin calcium excellent in stability, is presented. In the production of a compound (pitavastatin calcium) represented by the formula (1): The water content is adjusted to a level of from 5 to 15%, and the crystal form is controlled to be crystal form A, thereby to obtain a drug substance excellent in stability.
摘要:
A method for producing a drug substance of crystalline pitavastatin calcium excellent in stability, is presented. In the production of a compound (pitavastatin calcium) represented by the formula (1): The water content is adjusted to a level of from 5 to 15%, and the crystal form is controlled to be crystal form A, thereby to obtain a drug substance excellent in stability.
摘要:
There is provided a process for efficiently producing an optically active substance of efonidipine that is useful as an antihypertensive agent or a therapeutic agent for angina pectoris. A process for producing an optically active substance of compound of formula (1) characterized by comprising: dissolving a racemate of the compound of formula (1) in a solvent to prepare a supersaturated solution; and adding crystal of either one optically active substance of the compound of formula (1) as a seed crystal in the supersaturated solution to allow crystal of the one optically active substance added as the seed crystal to separate out; or dissolving a mixture of the compound of formula (1) in which either one optically active substance thereof is present in excess in a solvent to prepare a supersaturated solution; and adding crystal of the one optically active substance present in excess as a seed crystal in the supersaturated solution to allow crystal of the one optically active substance present in excess to separate out.
摘要:
A process for producing a high purity 3,5-dihydroxy6-heptenoic acid derivative by controlling the content of impurities such as denatured substances, is provided. When a 3,5-dihydroxy-6-heptenoic acid derivative is produced by a process which comprises a step of contacting the 3,5-dihydroxy-6-heptenoic acid derivative of the formula (1) wherein R is a C1-4 alkyl group, with a C1-4 lower alcohol-containing solvent, an alcohol containing solvent having its content of an oxidizing substance lowered, is used to at most 0.05 molar equivalent to a 3,5-dihydroxy-6-heptenoic acid derivative, to suppress impurities contained in the 3,5-dihydroxy-6heptenoic acid derivative.
摘要翻译:提供了通过控制诸如变性物质等杂质的含量来生产高纯度3,5-二羟基-6-庚烯酸衍生物的方法。 当3,5-二羟基-6-庚烯酸衍生物通过包括使式(1)的3,5-二羟基-6-庚烯酸衍生物与其中R为C 1 -C 6烷基的式 1-4 C 1-4烷基与含C 1-4低级醇的溶剂,其含有氧化物质含量的醇的溶剂的含量最低为0.05摩尔当量 与3,5-二羟基-6-庚烯酸衍生物反应,以抑制3,5-二羟基-6-庚烯酸衍生物中所含的杂质。
摘要:
A method for producing an alkyl (3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxy-6-heptenoate of the formula (1) (wherein R is a C1-4 alkyl group), which is an intermediate for a cholesterol-reducing agent (a HMG-CoA reductase inhibitor), etc. A solution containing a compound of the formula (1) is subjected to liquid chromatography treatment using silica gel as the packing material, to separate its epimers contained therein.
摘要:
A method for producing an alkyl (3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxy-6-heptenoate of the formula (1) (wherein R is a C1-4 alkyl group), which is an intermediate for a cholesterol-reducing agent (a HMG-CoA reductase inhibitor), etc. A solution containing a compound of the formula (1) is subjected to liquid chromatography treatment using silica gel as the packing material, to separate its epimers contained therein.
摘要:
A process for producing a high purity 3,5-dihydroxy6-heptenoic acid derivative by controlling the content of impurities such as denatured substances, is provided. When a 3,5-dihydroxy-6-heptenoic acid derivative is produced by a process which comprises a step of contacting the 3,5-dihydroxy-6-heptenoic acid derivative of the formula (1) wherein R is a C1-4 alkyl group, with a C1-4 lower alcohol-containing solvent, an alcohol containing solvent having its content of an oxidizing substance lowered, is used to at most 0.05 molar equivalent to a 3,5-dihydroxy-6-heptenoic acid derivative, to suppress impurities contained in the 3,5-dihydroxy-6heptenoic acid derivative.
摘要:
A process for producing 2-cyclopropyl-4-(4-fluorophenyl)-quinoline-3-carbaldehyde, which entails oxidizing 2-cyclopropyl-4-(4-fluorophenyl)-3-hydroxymethylquinoline with a salt of a hypohalogenous acid in the presence of a quaternary ammonium salt.
摘要:
The process for preparing mevalonolactone compounds is carried out by means of batch system chromatography or a simulated moving bed chromatographic process using columns filled with an optical resolution filler comprising a polysaccharide derivative. The simulated moving bed chromatographic process comprises forming a circulation flow circuit comprising a plurality of columns endlessly connected in series; enforcing a fluid to flow through the circuit in one direction; providing the column series alternately with an inlet port through which the fluid is introduced into the column in the flow direction and with an outlet port, through which the fluid is taken out; intermittently shifting activation of the inlet port and the outlet port in the direction of the fluid flow; introducing a solution containing a racemic mevalonolactone compound and an eluent through an inlet port into the circuit; and simultaneously taking out a solution rich in the weakly adsorbable substance and a solution rich in the strongly adsorbable and desorbed substance through the outlet port.